Amgen Inc Stock Performance
| AMGN Stock | USD 294.53 4.63 1.60% |
The firm shows a Beta (market volatility) of 0.98, which signifies possible diversification benefits within a given portfolio. Amgen returns are very sensitive to returns on the market. As the market goes up or down, Amgen is expected to follow. At this point, Amgen Inc has a negative expected return of -0.14%. Please make sure to confirm Amgen's potential upside, and the relationship between the jensen alpha and daily balance of power , to decide if Amgen Inc performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Amgen Inc has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest conflicting performance, the Stock's technical and fundamental indicators remain healthy and the recent disarray on Wall Street may also be a sign of long period gains for the firm investors. ...more
Actual Historical Performance (%)
One Day Return 0.65 | Five Day Return 0.0978 | Year To Date Return (1.88) | Ten Year Return 77.72 | All Time Return 84.8 K |
Forward Dividend Yield 0.031 | Payout Ratio 0.4683 | Last Split Factor 2:1 | Forward Dividend Rate 9 | Dividend Date 2024-12-09 |
| Amgen dividend paid on 6th of September 2024 | 09/06/2024 |
1 | Fiducient Advisors LLC Decreases Stock Position in Amgen Inc. | 10/31/2024 |
2 | Vitrian Closes on 50M Initial Investment into Biomanufacturing Capacity in Central Ohio and Launches Partnership with AmplifyBio | 11/05/2024 |
3 | Bensler LLC Purchases 1,472 Shares of Amgen Inc. | 11/08/2024 |
4 | Whats Happening With Amgen Stock | 11/13/2024 |
5 | 2 Dividend Stocks to Buy Hand Over Fist in November | 11/14/2024 |
6 | BeiGene anuncia los resultados financieros del tercer trimestre de 2024 y otras novedades corporativas | 11/15/2024 |
7 | Celltrion presents additional data from phase III randomized controlled trials to further support biosimilarity for CT-41 and CT-P47 at American College of Rheu... | 11/18/2024 |
8 | Celiac Disease Pipeline Grows as 25 Key Pharma Companies Join the Fight for Innovative Treatments DelveInsight | 11/19/2024 |
9 | AMGEN ANNOUNCES SENIOR EXECUTIVE RESEARCH APPOINTMENT | 11/20/2024 |
| Begin Period Cash Flow | 7.6 B | |
| Total Cashflows From Investing Activities | -26.2 B |
Amgen |
Amgen Relative Risk vs. Return Landscape
If you would invest 32,419 in Amgen Inc on August 24, 2024 and sell it today you would lose (2,966) from holding Amgen Inc or give up 9.15% of portfolio value over 90 days. Amgen Inc is currently does not generate positive expected returns and assumes 1.5859% risk (volatility on return distribution) over the 90 days horizon. In different words, 14% of stocks are less volatile than Amgen, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Amgen Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Amgen's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Amgen Inc, and traders can use it to determine the average amount a Amgen's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0865
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | AMGN |
Estimated Market Risk
| 1.59 actual daily | 14 86% of assets are more volatile |
Expected Return
| -0.14 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.09 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Amgen is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Amgen by adding Amgen to a well-diversified portfolio.
Amgen Fundamentals Growth
Amgen Stock prices reflect investors' perceptions of the future prospects and financial health of Amgen, and Amgen fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Amgen Stock performance.
| Return On Equity | 0.56 | ||||
| Return On Asset | 0.046 | ||||
| Profit Margin | 0.13 % | ||||
| Operating Margin | 0.24 % | ||||
| Current Valuation | 206.13 B | ||||
| Shares Outstanding | 537.53 M | ||||
| Price To Earning | 22.74 X | ||||
| Price To Book | 20.56 X | ||||
| Price To Sales | 4.79 X | ||||
| Revenue | 28.19 B | ||||
| Gross Profit | 19.92 B | ||||
| EBITDA | 7.9 B | ||||
| Net Income | 6.72 B | ||||
| Cash And Equivalents | 11.48 B | ||||
| Cash Per Share | 21.51 X | ||||
| Total Debt | 64.61 B | ||||
| Current Ratio | 1.68 X | ||||
| Book Value Per Share | 14.00 X | ||||
| Cash Flow From Operations | 8.47 B | ||||
| Earnings Per Share | 7.83 X | ||||
| Market Capitalization | 155.83 B | ||||
| Total Asset | 97.15 B | ||||
| Retained Earnings | (26.55 B) | ||||
| Working Capital | 11.94 B | ||||
| Current Asset | 38.52 B | ||||
| Current Liabilities | 8.67 B | ||||
About Amgen Performance
By examining Amgen's fundamental ratios, stakeholders can obtain critical insights into Amgen's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Amgen is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 411.08 | 217.06 | |
| Return On Tangible Assets | 0.15 | 0.12 | |
| Return On Capital Employed | 0.10 | 0.10 | |
| Return On Assets | 0.07 | 0.12 | |
| Return On Equity | 1.08 | 1.13 |
Things to note about Amgen Inc performance evaluation
Checking the ongoing alerts about Amgen for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Amgen Inc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Amgen Inc generated a negative expected return over the last 90 days | |
| Amgen Inc has a poor financial position based on the latest SEC disclosures | |
| Over 81.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: AMGEN ANNOUNCES SENIOR EXECUTIVE RESEARCH APPOINTMENT |
- Analyzing Amgen's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Amgen's stock is overvalued or undervalued compared to its peers.
- Examining Amgen's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Amgen's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Amgen's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Amgen's stock. These opinions can provide insight into Amgen's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amgen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amgen. If investors know Amgen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amgen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.621 | Dividend Share 8.88 | Earnings Share 7.83 | Revenue Per Share 60.641 | Quarterly Revenue Growth 0.232 |
The market value of Amgen Inc is measured differently than its book value, which is the value of Amgen that is recorded on the company's balance sheet. Investors also form their own opinion of Amgen's value that differs from its market value or its book value, called intrinsic value, which is Amgen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amgen's market value can be influenced by many factors that don't directly affect Amgen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amgen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Amgen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amgen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.